目的觀察臨床常用的免疫抑制劑對(duì)急性胰腺炎時(shí)炎癥相關(guān)性細(xì)胞因子紊亂的調(diào)節(jié)作用，并探討免疫抑制劑治療胰腺炎的效果和機(jī)理。方法實(shí)驗(yàn)用雄性SD 大鼠38只, 共分6組： 正常對(duì)照組（n=6）； 胰腺炎組 (n=8)，采用開腹胰管注射5%?；悄懰徕c制備急性胰腺炎動(dòng)物模型； 余下4組（均為n=6）在胰腺炎誘導(dǎo)成功后0.5 h按靜脈注射藥物不同分為: 5Fu治療組、甲基強(qiáng)的松龍治療組、環(huán)磷酰胺治療組及氨甲碟呤治療組。手術(shù)后24 h處死動(dòng)物，分別檢查血中TNFα、IL1、IL6、IL10、TGFβ及胰淀粉酶和胰腺濕重。結(jié)果在急性胰腺炎時(shí)，動(dòng)物血中的炎癥性細(xì)胞因子和抗炎癥細(xì)胞因子均顯著增高，在使用免疫抑制劑治療后，上述細(xì)胞因子均有不同程度下降。其血胰淀粉酶和胰腺濕重也明顯好轉(zhuǎn)。 結(jié)論免疫抑制劑可以抑制急性胰腺炎時(shí)異常增高的炎癥細(xì)胞因子和抗炎癥細(xì)胞因子。通過矯正免疫異常的方式緩解胰腺炎所致的病理生理紊亂，達(dá)到治療急性胰腺炎的目的。
引用本文： 陳曉理,黃興蘭, 吳浩, 吳曉娟. 常用免疫抑制劑對(duì)急性胰腺炎免疫異常的調(diào)節(jié)作用. 中國(guó)普外基礎(chǔ)與臨床雜志, 2002, 9(6): 384-387. doi: 復(fù)制
| 1. | de Beaux AC, Ross JA, Maingay JP, et al. Proinflammatory cytokine release by peripheral blood mononuclear cells from patients with acute pancreatitis [Ｊ]. Br J Surg， 1996; 83(8)∶1071. |
| 2. | McKay CJ, Gallagher H, Brooks B, et al. Increased monocyte cytokine production in association with systemic complications in acute pancreatitis [Ｊ]. Br J Surg， 1996; 83(7)∶919. |
| 3. | de Beaux AC, Goldie AS, Ross JA, et al. Serum concentrations of inflammatory mediators related to organ failure in patients with acute pancreatitis [Ｊ]. Br J Surg， 1996; 83(3)∶349. |
| 4. | 崔潤(rùn)林. 5Fu治療急性胰腺炎的初步觀察 [Ｊ]. 實(shí)用內(nèi)科雜志， 1983； 3（5）∶246. |
| 5. | 譚下宇 . 5氟尿嘧啶配合腹腔引流治療急性胰腺炎的初步體會(huì) [Ｊ]. 中華醫(yī)學(xué)雜志, 1985； 65（12）∶757. |
| 6. | Saarrio IA. 5fluorouracil in the treatment of acute pancreatitis [Ｊ]. Am J Surg,1983; 145(3)∶349. |
| 7. | Kimura K,Shimosegawa T,Sasano H，et al.Endogenous glucocorticoids decrease the acinar cell sensitivity to apoptosis during cerulein pancreatitis in rats [Ｊ].Gastroenterology,1998; 114(2)∶372. |
| 8. | Darville T， Giroir B， Jacobs R. The systemic inflammatory response syndrome (SIRS): immunology and potential immunotherapy [Ｊ]. Infection, 1993; 21(5)∶279. |
| 9. | Schlag G, Redl H. Mediators of injury and inflammation [Ｊ]. World J Surg,1996； 20(4)∶406. |
| 10. | Dinarello CA， Gelfand JA， Wolff SM. Anticytokine strategies in the treatment of the systemic inflammatory response syndrome [Ｊ]. JAMA,1993; 269(14)∶1829. |
| 11. | Iwagaki H，Hizuta A， Uomoto M，et al. Clinical value of cytokine antagonists in infectious complications [Ｊ].Res Commun Mol Pathol Pharmacol, 1997； 96(1)∶25. |
| 12. | Artels H, Zantl N, Holzmann B, et al. Special therapeutic approaches for interrupting the cascadefrom SIRS to MOF [Ｊ]. Langenbecks Arch Chir Suppl Kongressbd, 1988; 115∶615. |
- 1. de Beaux AC, Ross JA, Maingay JP, et al. Proinflammatory cytokine release by peripheral blood mononuclear cells from patients with acute pancreatitis [Ｊ]. Br J Surg， 1996; 83(8)∶1071.
- 2. McKay CJ, Gallagher H, Brooks B, et al. Increased monocyte cytokine production in association with systemic complications in acute pancreatitis [Ｊ]. Br J Surg， 1996; 83(7)∶919.
- 3. de Beaux AC, Goldie AS, Ross JA, et al. Serum concentrations of inflammatory mediators related to organ failure in patients with acute pancreatitis [Ｊ]. Br J Surg， 1996; 83(3)∶349.
- 4. 崔潤(rùn)林. 5Fu治療急性胰腺炎的初步觀察 [Ｊ]. 實(shí)用內(nèi)科雜志， 1983； 3（5）∶246.
- 5. 譚下宇 . 5氟尿嘧啶配合腹腔引流治療急性胰腺炎的初步體會(huì) [Ｊ]. 中華醫(yī)學(xué)雜志, 1985； 65（12）∶757.
- 6. Saarrio IA. 5fluorouracil in the treatment of acute pancreatitis [Ｊ]. Am J Surg,1983; 145(3)∶349.
- 7. Kimura K,Shimosegawa T,Sasano H，et al.Endogenous glucocorticoids decrease the acinar cell sensitivity to apoptosis during cerulein pancreatitis in rats [Ｊ].Gastroenterology,1998; 114(2)∶372.
- 8. Darville T， Giroir B， Jacobs R. The systemic inflammatory response syndrome (SIRS): immunology and potential immunotherapy [Ｊ]. Infection, 1993; 21(5)∶279.
- 9. Schlag G, Redl H. Mediators of injury and inflammation [Ｊ]. World J Surg,1996； 20(4)∶406.
- 10. Dinarello CA， Gelfand JA， Wolff SM. Anticytokine strategies in the treatment of the systemic inflammatory response syndrome [Ｊ]. JAMA,1993; 269(14)∶1829.
- 11. Iwagaki H，Hizuta A， Uomoto M，et al. Clinical value of cytokine antagonists in infectious complications [Ｊ].Res Commun Mol Pathol Pharmacol, 1997； 96(1)∶25.
- 12. Artels H, Zantl N, Holzmann B, et al. Special therapeutic approaches for interrupting the cascadefrom SIRS to MOF [Ｊ]. Langenbecks Arch Chir Suppl Kongressbd, 1988; 115∶615.